热门资讯> 正文
Seer对Nanomics Biotechnology提起专利侵权诉讼
2026-05-13 19:57
- Seer (SEER) on Wednesday said it filed a patent infringement lawsuit against Nanomics Biotechnology, alleging infringement of five U.S. patents tied to nanoparticle protein enrichment technology.
- Brigham and Women’s Hospital joined the lawsuit, which centers on intellectual property used in Seer’s Proteograph product suite.
- Seer alleged Nanomics infringed the patents through its Proteonano kits and workstations and said it is seeking monetary damages and injunctive relief. CEO Omid Farokhzad said the company would aggressively defend its proteomics technology portfolio.
More on Seer
- Seer, Inc. 2025 Q4 - Results - Earnings Call Presentation
- Seer, Inc. (SEER) Q4 2025 Earnings Call Transcript
- Seer gets sweetened buyout offer from activist group
- Key deals this week: American Express, Otis, Vertiv, Wipro and more
- Seeking Alpha’s Quant Rating on Seer
风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。